Literature DB >> 18334580

The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Lynnette K Nieman1, Beverly M K Biller, James W Findling, John Newell-Price, Martin O Savage, Paul M Stewart, Victor M Montori.   

Abstract

OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments.
CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334580      PMCID: PMC2386281          DOI: 10.1210/jc.2008-0125

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  106 in total

1.  Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure.

Authors:  A Colao; R Pivonello; S Spiezia; A Faggiano; D Ferone; M Filippella; P Marzullo; G Cerbone; M Siciliani; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

2.  Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests.

Authors:  M Castro; P C Elias; A R Quidute; F P Halah; A C Moreira
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

3.  The natural history of Cushing's syndrome.

Authors:  C M PLOTZ; A I KNOWLTON; C RAGAN
Journal:  Am J Med       Date:  1952-11       Impact factor: 4.965

Review 4.  Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses.

Authors:  Mohamed B Elamin; M Hassan Murad; Rebecca Mullan; Dana Erickson; Katherine Harris; Sarah Nadeem; Robert Ennis; Patricia J Erwin; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

5.  A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system.

Authors:  Brian A Swiglo; M H Murad; Holger J Schünemann; Regina Kunz; Robert A Vigersky; Gordon H Guyatt; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-01-02       Impact factor: 5.958

6.  Incidence and late prognosis of cushing's syndrome: a population-based study.

Authors:  J Lindholm; S Juul; J O Jørgensen; J Astrup; P Bjerre; U Feldt-Rasmussen; C Hagen; J Jørgensen; M Kosteljanetz; L Kristensen; P Laurberg; K Schmidt; J Weeke
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

7.  Long-term mortality after transsphenoidal surgery for Cushing disease.

Authors:  B Swearingen; B M Biller; F G Barker; L Katznelson; S Grinspoon; A Klibanski; N T Zervas
Journal:  Ann Intern Med       Date:  1999-05-18       Impact factor: 25.391

8.  Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism.

Authors:  Isabelle Bourdeau; Céline Bard; Bernard Noël; Isabelle Leclerc; Marie-Pierre Cordeau; Manon Bélair; Jacques Lesage; Lucie Lafontaine; André Lacroix
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

9.  Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group.

Authors:  R Görges; G Knappe; H Gerl; M Ventz; F Stahl
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

10.  Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis.

Authors:  C Invitti; F Pecori Giraldi; M de Martin; F Cavagnini
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

View more
  540 in total

1.  Children with Cushing's syndrome: Primary Pigmented Nodular Adrenocortical Disease should always be suspected.

Authors:  Renata Marques Gonçalves da Silva; Emília Pinto; Suzan M Goldman; Cássio Andreoni; Teresa C Vieira; Julio Abucham
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

2.  Short-term and long-term orthopaedic issues in patients with fragility fractures.

Authors:  Susan V Bukata; Stephen L Kates; Regis J O'Keefe
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

3.  Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing's syndrome using an automated immunoassay system.

Authors:  C A Carrasco; M García; M Goycoolea; J Cerda; J Bertherat; O Padilla; D Meza; N Wohllk; T Quiroga
Journal:  Endocrine       Date:  2012-01-24       Impact factor: 3.633

4.  Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing's syndrome.

Authors:  Zhanna E Belaya; Alexander V Iljin; Galina A Melnichenko; Liudmila Y Rozhinskaya; Natalia V Dragunova; Larisa K Dzeranova; Svetlana A Butrova; Ekaterina A Troshina; Ivan I Dedov
Journal:  Endocrine       Date:  2012-03-25       Impact factor: 3.633

5.  Salivary cortisol and the diagnosis of Cushing's syndrome: a coming of age.

Authors:  Hershel Raff
Journal:  Endocrine       Date:  2012-06       Impact factor: 3.633

Review 6.  Harmful effects of functional hypercortisolism: a working hypothesis.

Authors:  Giacomo Tirabassi; Marco Boscaro; Giorgio Arnaldi
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

7.  Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.

Authors:  V Guarnotta; G Pizzolanti; A Ciresi; C Giordano
Journal:  J Endocrinol Invest       Date:  2018-02-02       Impact factor: 4.256

8.  Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States.

Authors:  Michael S Broder; Maureen P Neary; Eunice Chang; Dasha Cherepanov; William H Ludlam
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 9.  Hypercortisolism in obesity-associated hypertension.

Authors:  Amy G Varughese; Oksana Nimkevych; Gabriel I Uwaifo
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

Review 10.  Cushing syndrome in pediatrics.

Authors:  Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2012-09-27       Impact factor: 4.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.